A Randomized Controlled Study of Propranolol for Prevention of Recurrent Gastrointestinal Bleeding in Patients with Cirrhosis: A Final Report

Hepatology - Tập 4 Số 3 - Trang 355-358 - 1984
Didier Lebrec1,2,3,4, Thierry Poynard1,2,3,4, Jacques Bernuau1,2,3,4, E Bercoff1,2,3,4, O Nouël1,2,3,4, Jean‐Pierre Capron1,2,3,4, Raoul Poupon1,2,3,4, Michel Bouvry1,2,3,4, B Rueff1,2,3,4, Jean‐Pierre Benhamou1,2,3,4
1Centre Hospitaller Uniuersltaire d'Amiens, Amiens, France
2Centre Hospitaller de Pontolse, Pontolse, France
3Hǒpital Salnt-Antolne, Paris, France
4Unité de Recherches de Physiopathologie Hépatlque (INSERM), Hopital Beaujon, Clichy, France

Tóm tắt

We have previously reported the results of a controlled trial showing that continuous oral administration of propranolol reduced the risk of recurrent gastrointestinal bleeding in patients with cirrhosis; only part of our patients had been followed for 1 year. This controlled trial was continued for an additional year; accordingly, all of our patients have now been followed for at least 2 years. The purpose of the present study is to determine whether prolonged administration enhances the efficacy of this therapy. Seventy-four patients with cirrhosis, admitted for an episode of gastrointestinal bleeding, were included in this study; ascites, jaundice and encephalopathy were absent or mild and transient. The patients were randomly assigned to two groups; one group of 38 patients received propranolol twice daily at doses that reduced the resting heart rate by 25%, the other group of 36 patients received a placebo twice daily. The cumulative percentages of patients free of recurrent gastrointestinal bleeding 1 and 2 years after inclusion were 87 and 79% in the propranolol group, and 42 and 32% in the placebo group; both differences were highly significant (p < 0.0001). Furthermore, the cumulative percentages of surviving patients 1 and 2 years after inclusion were 94 and 90% in the propranolol group, and 84 and 57% in the placebo group; the difference between the two groups was not significant at 1 year, but was statistically significant at 2 years (p < 0.02). We conclude that, in patients with cirrhosis in good condition, propranolol reduced the risk of recurrent gastrointestinal bleeding and the mortality rate during the 2-year period of continuous oral administration of the drug.

Từ khóa


Tài liệu tham khảo

Lebrec, 1981, Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study, N Engl J Med, 305, 1371, 10.1056/NEJM198112033052302

Peto, 1977, Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples, Br J Cancer, 35, 1, 10.1038/bjc.1977.1

Graham, 1981, The course of patients after variceal hemorrhage, Gastroenterology, 80, 800, 10.1016/0016-5085(81)90144-X

MacDougall, 1982, Increased long-term survival in variceal haemorrhage using injection sclerotherapy. Results of a controlled trial, Lancet, 2, 124, 10.1016/S0140-6736(82)90378-6

Lebrec, 1982, The effect of propranolol on portal hypertension in patients with cirrhosis: a hemodynamic study, Hepatology, 2, 523, 10.1002/hep.1840020502

Textor, 1982, Redistribution of cardiac output to the kidneys during oral nadolol administration, N Engl J Med, 307, 601, 10.1056/NEJM198209023071007

Kosinski, 1973, Glucagon and isoproterenol in reversing propranolol toxicity, Arch Intern Med, 132, 840, 10.1001/archinte.1973.03650120048009

Richards, 1978, Self-poisoning with beta-blockers, Br Med J, 1, 1623, 10.1136/bmj.1.6127.1623-c

Opie, 1980, Drugs and the heart. I. Beta-blocking agents, Lancet, 1, 693, 10.1016/S0140-6736(80)92839-1

Thông tin
Thông tin xuất bản

Hepatology

Tập 4 Số 3

355-358

Thông tin tác giả